Get the Stockscreener App
2.10
0.48%
0.01
Pre-market:
2.03
-0.07
-3.33%
Mural Oncology Plc stock is traded at $2.10, with a volume of 48,909.
It is up +0.48% in the last 24 hours and up +0.48% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.09
Open:
$2.1
24h Volume:
48,909
Relative Volume:
0.34
Market Cap:
$36.42M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.48%
6M Performance:
-23.64%
1Y Performance:
-45.74%
1-Day Range:
$2.09
$2.10
1-Week Range:
$2.08
$2.10
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.10 | 36.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Citadel Group discloses 1.38% stake in Mural Oncology By Investing.com - Investing.com South Africa
Form 8.3The Vanguard Group, Inc.: Mural Oncology plc - TradingView
Mural Oncology plc (MURA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Citadel Group discloses 1.32% stake in Mural Oncology - Investing.com
REGCitadel Group Mural Oncology PLCForm 8.3Mural Oncology plc - TradingView
What drives Mural Oncology plc stock priceLow Risk Investment Ideas & Rapid Capital Gain - earlytimes.in
Is Mural Oncology plc stock attractive for ETFsJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Why Mural Oncology plc stock remains a top recommendation - newser.com
Will Mural Oncology plc stock benefit from green energy trendsTrade Entry Report & Safe Capital Growth Plans - newser.com
Citadel Group discloses 1.32% stake in Mural Oncology By Investing.com - Investing.com Nigeria
Is Mural Oncology plc stock ready for a breakoutJuly 2025 Chart Watch & Momentum Based Trading Ideas - newser.com
Citadel discloses 1.31% stake in Mural Oncology - Investing.com India
Citadel discloses 1.31% stake in Mural Oncology By Investing.com - Investing.com Canada
What candlestick patterns are forming on Mural Oncology plcJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Is Mural Oncology plc a candidate for recovery playJuly 2025 Trade Ideas & Entry Point Confirmation Signals - newser.com
Citadel Group discloses 1.3% stake in Mural Oncology By Investing.com - Investing.com South Africa
Citadel Group discloses 1.3% stake in Mural Oncology - Investing.com India
Why Mural Oncology plc stock is favored by pension fundsWeekly Trade Recap & Daily Profit Maximizing Trade Tips - newser.com
Citadel Group discloses 1.26% stake in Mural Oncology By Investing.com - Investing.com Canada
Citadel Group discloses 1.26% stake in Mural Oncology - Investing.com India
Is it too late to sell Mural Oncology plcPortfolio Profit Report & Community Supported Trade Ideas - newser.com
How Mural Oncology plc stock performs during Fed tightening cyclesPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - newser.com
Combining price and volume data for Mural Oncology plc - newser.com
Is Mural Oncology plc stock attractive for growth ETFsEarnings Risk Report & Detailed Earnings Play Strategies - newser.com
Citadel Group discloses 1.23% stake in Mural Oncology By Investing.com - Investing.com Australia
Citadel Group discloses 1.23% stake in Mural Oncology - Investing.com
Mural Oncology plc Stock Analysis and ForecastPrice Action Trading & Discover Top Gainers in Every Sector - earlytimes.in
What analysts say about Mural Oncology plc stockSector Rotation Strategies & Get The Analyst Consensus With One Click - earlytimes.in
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Mural Oncology Plc Stock (MURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Goodman Vicki L | Chief Medical Officer |
Nov 10 '25 |
Sale |
2.08 |
5,036 |
10,475 |
84,727 |
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):